INBRAIN Neuroelectronics

INBRAIN Neuroelectronics is a neurotechnology company pushing a very specific materials-driven bet: graphene electrodes, fabricated with semiconductor-style processes, as a path to higher-resolution sensing and safer, more stable stimulation than traditional metal electrodes.

Unlike many BCI companies whose public narrative is dominated by cursor control or typing demos, INBRAIN frames its core product as BCI-Tx (therapeutic BCI): decoding biomarkers and then modulating circuits with micrometer-scale targeting.

Company background

• Website: ⁰¹
• Core platform claim (company): “skin-like, bi-directional, high resolution (up to 1024 contacts)” cortical interfaces + implantable processor + AI platform; FDA Breakthrough Device Designation for Parkinson’s use (per company). ⁰¹

• Funding (2026): INBRAIN announced a $50M Series B. Source: ⁰²

The technology thesis: why graphene?

Graphene is attractive here because it is conductive carbon rather than a metal, and INBRAIN argues this changes the long-run electrochemistry of stimulation/recording interfaces.

IEEE Spectrum’s coverage summarizes INBRAIN’s argument:

• metallic electrodes can undergo Faradaic reactions in aqueous tissue environments, degrading effectiveness over time

• graphene can support high charge injection while avoiding the same failure mode, potentially improving stability over many stimulation pulses

• IEEE Spectrum (Jul 23, 2024): “New Brain-Computer Interface Uses Graphene” ⁰³

INBRAIN’s own platform description emphasizes:

• high charge injection capacity + low electrical impedance → reduced power requirements → miniaturization

• flexible, “skin-like” high-resolution interfaces

• Company site: ⁰¹

• MINIGRAPH results (Oct 7, 2026, company press release): INBRAIN announced completion and results of MINIGRAPH, a European Innovation Council funded project coordinated by ICN2. Other consortium members: imec, Fraunhofer-Gesellschaft, Leiden University Medical Center, ETH Zurich, Nanoflex Robotics and Palacky University Olomouc. Per the release, Nanoflex Robotics and ETH Zurich built a magnetically guided robotic system that deployed ultra-thin cortical and subcortical graphene probes along straight and curved trajectories under X-ray imaging, validated in vitro and in vivo in a large animal model. The consortium also reports accelerated-ageing data supporting more than 10 years of projected stability, and compact implantable electronics decoding signals from hundreds of neural sites. Parkinson’s disease was the initial application. All results are company-reported from the press release, and this work was preclinical, not human. Separately, INBRAIN has a collaboration with Robeauté that is not part of MINIGRAPH. Source: ⁰⁴

Interface design: high-density cortical film + precision surgery wedge

A key near-term wedge for high-density cortical interfaces is intraoperative mapping / precision neurosurgery.

INBRAIN reports a first-in-human use as part of tumor resection workflow:

• the cortical interface is used to monitor brain activity and help distinguish cancerous vs healthy tissue during resection
• performed at Salford Royal Hospital (Manchester)
• described as part of a clinical study sponsored by the University of Manchester
• the initial human study is described as 8–10 patients, aimed primarily at demonstrating graphene safety in direct brain contact

Primary institutional sources:

• University of Manchester news post (Sep 26, 2024): ⁰⁵
• ICN2 (Institut Català de Nanociència i Nanotecnologia) news post (Sep 27, 2024): ⁰⁶
• BIST repost/summary (Barcelona Institute of Science and Technology): ⁰⁷

Therapeutic direction: Parkinson’s and closed-loop precision neuromodulation

INBRAIN’s public messaging places its platform in the closed-loop neuromodulation lane:

• decode biomarkers in real time

• modulate cortical/subcortical structures with high precision

• Company site: ⁰¹

IEEE Spectrum notes INBRAIN received FDA Breakthrough Device Designation for its system as an adjunctive therapy in Parkinson’s disease, and discusses a strategy of decoding intention + pathological biomarkers (tremor/rigidity/freezing), with the longer-term goal of targeted therapy.

• IEEE Spectrum: ⁰³

Clinical progress

• Clinical: the company announced completion of patient recruitment in its first-in-human graphene study on Apr 20, 2026. Source: ⁰⁸

What to watch

1. Chronic stability and safety The intraoperative/tumor-resection context is a pragmatic first step, but the real test is chronic implantation: stability of impedance, encapsulation, and stimulation safety over long durations.

2. “High resolution” → clinical value High-density recordings can be impressive; the question is whether they translate into better outcomes (better resection margins, fewer deficits, or better control/therapy in movement disorders).

3. Regulatory clarity The reported Breakthrough Device Designation for Parkinson’s needs confirmation against an FDA listing or a primary company announcement.